Q-omics provides the consensus-scored ASPHD1 profile across patient tissues and cancer cell-line models. ASPHD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ASPHD1 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, ASPHD1 RNA expression shows 17,746 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KIRP, and TGCT as cancer lineages where ASPHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASPHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASPHD1 survival associations across molecular data types. ASPHD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASPHD1 RNA expression–survival associations across cancer types. High ASPHD1 expression shows unfavorable associations in UCS, ACC, UCEC and COAD, but favorable associations in UVM and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ASPHD1 RNA expression.
This table summarizes ASPHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ASPHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASPHD1 shows higher tumor expression in KIRP, KIRC, THCA, LUAD, COAD and HNSC. The KIRP box plot shows higher ASPHD1 RNA expression in tumor versus normal tissue (log2 FC = +3.429, t-test p < 0.001).
This table shows molecular features associated with ASPHD1 in patient tissues and cancer cell lines. In patient samples, ASPHD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ASPHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
